Archive July 2009

FDA approves new drug treatment for type 2 diabetes

Jul31

WASHINGTON, Jul 31, 2009 (Xinhua via COMTEX) The U.S. Food and DrugAdministration on Friday approved Onglyza (saxagliptin), aonce-daily tablet to treat Type 2 diabetes in adults. Themedication is intended to be used with diet and exercise tocontrol high blood sugar levels.The hormone insulin keeps blood sugar (glucose) levels within anarrow range in people who don’t […]

PCMA Statement on U.S. House Energy and Commerce Committee Health Care Reform Markup

Jul31

WASHINGTON(BUSINESS WIRE) The Pharmaceutical Care Management Association (PCMA) issued the following statement on the amendments contained in the U.S. of Representatives House Energy and Commerce Committee markup of the tri-committee majority health reform bill: While today’s vote is a testament to the ongoing power of the drug industry, which has spent more than $66 million […]

House Tri-Committee Bill Would Hurt Patients and Kill Jobs

Jul31

WASHINGTON, July 31 /PRNewswire-USNewswire/ Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson released the following statement after the Energy and Commerce Committee mark-up of the House Tri-Committee bill:"PhRMA remains committed to working with the Administration and Congress to help enact comprehensive health care reform this year. Our policy agreement with the […]

DC PhRMA health bill

Jul31

BC-DC-PhRMA-health-billTo: POLITICAL EDITORSContact: Jennifer Wall of PhRMA, +1-202-835-3460WASHINGTON, July 31 /PRNewswire-USNewswire/ Pharmaceutical Research andManufacturers of America (PhRMA) Senior Vice President Ken Johnson releasedthe following statement after the Energy and Commerce Committee mark-up of theHouse Tri-Committee bill:"PhRMA remains committed to working with the Administration and Congressto help enact comprehensive health care reform this year. Our policyagreement […]

Onglyza approved for Type 2 Diabetes

Jul31

The drug Onglyza has been approved for use by Type 2 adult diabetics, the U.S. Food and Drug Administration said.Also known as saxagliptin, the drug is tended to be taken once a day in tablet form and used with diet and exercise to control high blood sugar levels, the FDA said in a release Friday.Onglyza, […]

U.S. FDA approves anti-psychotic drug

Jul31

Invega Sustenna, a longer-acting anti-psychotic medication for schizophrenia, has been approved by the U.S. Food and Drug Administration, its maker says.Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals Inc., said in a release Friday its once-monthly injectable version of the drug paliperidone palmitate became the first of its kind to be approved in the United States."The approval […]

Scientists at University of Liverpool report research in hypersensitivity therapy

Jul30

2009 JUL 31 – (NewsRx.com) Scientists discuss in ‘Medication errors: the importance of an accurate drug history’ new findings in hypersensitivity (see also Hypersensitivity Therapy). "1. Medication histories are important in preventing prescription errors and consequent risks to patients," scientists writing in the British Journal of Clinical Pharmacology report."Apart from preventing prescription errors, accurate medication […]

meridianEMR Completes Surescripts(R) Certification

Jul30

2009 JUL 31 – (NewsRx.com) meridianEMR, a leading provider of electronic medical records systems, electronic prescribing and advanced healthcare analytics, announced that it has completed certification with Surescripts on June 24th, 2009. meridianEMR users will now be able to electronically and securely exchange prescription information directly with pharmacies and payers in communities throughout all 50 […]

Strategic Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets

Jul30

2009 JUL 31 – (NewsRx.com) Research and Markets has announced the addition of Decision Resources, Inc.’s new report "Strategic Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets" to their offering (see also Research and Markets).Around the world, the market success of branded drugs is influenced by changes in healthcare systems and the growing […]

GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients

Jul30

2009 JUL 31 – (NewsRx.com) The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger on the Senate HELP Committee’s vote on biogenerics legislation (see also Pharmaceuticals)."While we are extremely disappointed that the Committee action could result in patients having little or no access to affordable biogenerics, we […]